CR20190351A - PROCESO PARA LA SINTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA (Divisional 2016-0252) - Google Patents

PROCESO PARA LA SINTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA (Divisional 2016-0252)

Info

Publication number
CR20190351A
CR20190351A CR20190351A CR20190351A CR20190351A CR 20190351 A CR20190351 A CR 20190351A CR 20190351 A CR20190351 A CR 20190351A CR 20190351 A CR20190351 A CR 20190351A CR 20190351 A CR20190351 A CR 20190351A
Authority
CR
Costa Rica
Prior art keywords
indoleamine
amino
synthesis
dioxygenase
inhibitor
Prior art date
Application number
CR20190351A
Other languages
English (en)
Inventor
Ming Tao
Lingkai Weng
William Frietze
David J Meloni
Yongchun Pan
Jiacheng Zhou
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of CR20190351A publication Critical patent/CR20190351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a procesos e intermedios para elaborar 4-({2-[(aminosulfonil)amino]etil}amino)-N-(3-bromo-4-fluorofenil)-N'-hidroxi-1,2,5-oxadiazol-3-carboximidamida, que es un inhibidor de indolamina 2,3-dioxigenasa útil en el tratamiento del cáncer y otros trastornos.The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.
CR20190351A 2013-11-08 2014-11-07 PROCESO PARA LA SINTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA (Divisional 2016-0252) CR20190351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361901689P 2013-11-08 2013-11-08
PCT/US2014/064531 WO2015070007A1 (en) 2013-11-08 2014-11-07 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Publications (1)

Publication Number Publication Date
CR20190351A true CR20190351A (es) 2019-10-07

Family

ID=52023608

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20160252A CR20160252A (es) 2013-11-08 2014-11-07 Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa
CR20190351A CR20190351A (es) 2013-11-08 2014-11-07 PROCESO PARA LA SINTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA (Divisional 2016-0252)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20160252A CR20160252A (es) 2013-11-08 2014-11-07 Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa

Country Status (31)

Country Link
US (3) US9321755B2 (es)
EP (2) EP3744715A1 (es)
JP (4) JP6461953B2 (es)
KR (2) KR102370067B1 (es)
CN (2) CN105899498B (es)
AR (1) AR098343A1 (es)
AU (2) AU2014346647B2 (es)
BR (2) BR122020009912B1 (es)
CA (1) CA2929552C (es)
CL (1) CL2016001082A1 (es)
CR (2) CR20160252A (es)
CY (1) CY1123164T1 (es)
DK (1) DK3066085T3 (es)
EA (2) EA201991770A1 (es)
ES (1) ES2799582T3 (es)
HR (1) HRP20201089T1 (es)
HU (1) HUE049337T2 (es)
IL (2) IL245314B (es)
LT (1) LT3066085T (es)
ME (1) ME03792B (es)
MX (2) MX366874B (es)
MY (1) MY174254A (es)
PE (2) PE20220430A1 (es)
PH (2) PH12016500818A1 (es)
PL (1) PL3066085T3 (es)
PT (1) PT3066085T (es)
RS (1) RS60598B1 (es)
SG (2) SG11201603433UA (es)
SI (1) SI3066085T1 (es)
TW (4) TW202309014A (es)
WO (1) WO2015070007A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101386494B1 (ko) 2005-05-10 2014-04-24 인사이트 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
KR101649548B1 (ko) 2008-07-08 2016-08-19 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
MX366874B (es) 2013-11-08 2019-07-29 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa.
SG11201606428UA (en) * 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
EP3322444A4 (en) * 2015-07-14 2019-06-12 Kyowa Hakko Kirin Co., Ltd. A TUMOR THERAPEUTIC AGENT COMPRISING AN IDO INHIBITOR ADMINISTERED IN ASSOCIATION WITH ANTIBODY
JP2018532756A (ja) 2015-11-04 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
WO2017106062A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
JP7035301B2 (ja) 2016-08-23 2022-03-15 北京諾誠健華医薬科技有限公司 縮合複素環誘導体、その調製方法、及びその医学的使用
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
CN110139857B (zh) * 2016-11-28 2023-07-21 重庆复尚源创医药技术有限公司 作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物
CN110382508B (zh) 2016-12-22 2022-08-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN109206380A (zh) * 2017-07-03 2019-01-15 上海时莱生物技术有限公司 吲哚胺2，3-双加氧酶抑制剂化合物及其制备方法和用途
CN110066253B (zh) * 2018-01-24 2023-06-23 江苏柯菲平医药股份有限公司 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用
CN108101899B (zh) * 2018-02-11 2021-01-26 中国药科大学 IDO1抑制剂Epacadostat中间体的制备方法
CN109180603A (zh) * 2018-10-10 2019-01-11 中国药科大学 Epacadostat关键中间体的制备方法
CA3148776A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
KR20220114551A (ko) * 2019-11-14 2022-08-17 노바 사우쓰이스턴 유니버시티 F16 이소인돌 소분자를 사용한 고형 종양의 치료 방법 및 조성물
CN112341403B (zh) * 2020-11-10 2022-06-28 南京工业大学 一种利用微流场反应技术制备3-氨基-4-偕胺肟基呋咱的方法
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (es) 1973-09-05 1981-05-16
DE2640484A1 (de) 1975-09-11 1977-04-07 Philagro Sa Amidoxim-derivate, ihre herstellung und verwendung
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
US4323681A (en) 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
JPS58208275A (ja) 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
DE3462259D1 (de) 1983-07-22 1987-03-05 Bayer Ag Substituted furazans
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
JP2696342B2 (ja) 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
DE68901424D1 (de) 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
JP2709677B2 (ja) 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
EE9800116A (et) 1995-10-17 1998-10-15 Astra Pharmaceuticals Limited Farmatseutiliselt aktiivsed kinasoliini ühendid
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
AU1628599A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan
PT1038874E (pt) 1997-12-10 2004-06-30 Dainippon Ink & Chemicals Derivados de oxima e produtos agro-quimicos que os contem
KR20010052491A (ko) 1998-06-02 2001-06-25 다케다 야쿠힌 고교 가부시키가이샤 옥사디아졸린 유도체 및 살충제로서 이의 용도
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AU763030B2 (en) 1999-03-03 2003-07-10 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
BR0009674A (pt) 1999-04-09 2002-01-15 Basf Ag Composto, droga, e, uso de composto
AU777594B2 (en) 1999-05-24 2004-10-21 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
AU2001239725A1 (en) 2000-01-13 2001-07-24 Tularik, Inc. Antibacterial agents
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
IL159219A0 (en) 2001-06-18 2004-06-01 Applied Research Systems Pyrrolidine oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
MXPA04008680A (es) 2002-02-19 2004-12-06 Pharmacia Italia Spa Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales.
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
WO2003087347A1 (en) 2002-04-12 2003-10-23 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
PL372246A1 (en) 2002-05-28 2005-07-11 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) * 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
JP4921965B2 (ja) 2003-03-27 2012-04-25 ランケナー インスティテュート フォー メディカル リサーチ 癌治療新規方式
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
CA2536253A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
JP4970946B2 (ja) 2004-09-08 2012-07-11 田辺三菱製薬株式会社 モルホリン化合物
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
KR101386494B1 (ko) 2005-05-10 2014-04-24 인사이트 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
EP1901789A2 (en) 2005-06-30 2008-03-26 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
WO2008036652A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008058178A1 (en) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2009128521A1 (ja) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 システインプロテアーゼ阻害剤
KR101649548B1 (ko) 2008-07-08 2016-08-19 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
MX366874B (es) 2013-11-08 2019-07-29 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa.

Also Published As

Publication number Publication date
DK3066085T3 (da) 2020-06-02
LT3066085T (lt) 2020-06-25
MY174254A (en) 2020-04-01
CA2929552A1 (en) 2015-05-14
MX2019008378A (es) 2019-09-09
TW201605817A (zh) 2016-02-16
JP2019038811A (ja) 2019-03-14
PE20220430A1 (es) 2022-03-29
AU2014346647B2 (en) 2018-10-25
CN109810104B (zh) 2022-05-03
SI3066085T1 (sl) 2020-08-31
EP3066085B1 (en) 2020-05-13
CR20160252A (es) 2016-09-19
TW201920158A (zh) 2019-06-01
SG10201803874PA (en) 2018-07-30
JP2020019805A (ja) 2020-02-06
PT3066085T (pt) 2020-07-16
US20180244663A1 (en) 2018-08-30
US9321755B2 (en) 2016-04-26
EA033667B1 (ru) 2019-11-14
MX2016005954A (es) 2016-12-07
TW202100523A (zh) 2021-01-01
BR122020009912B1 (pt) 2022-11-01
CN105899498B (zh) 2019-01-25
IL245314B (en) 2019-07-31
US9873688B2 (en) 2018-01-23
JP2017500284A (ja) 2017-01-05
AU2019200404A1 (en) 2019-02-07
EA201690959A1 (ru) 2016-08-31
ES2799582T3 (es) 2020-12-18
PH12019500770A1 (en) 2020-09-21
JP6913725B2 (ja) 2021-08-04
US20160221996A1 (en) 2016-08-04
CN109810104A (zh) 2019-05-28
EP3744715A1 (en) 2020-12-02
BR112016009786B1 (pt) 2021-01-05
AU2014346647A1 (en) 2016-05-26
CA2929552C (en) 2022-05-17
RS60598B1 (sr) 2020-08-31
TWI696618B (zh) 2020-06-21
SG11201603433UA (en) 2016-05-30
KR20160094971A (ko) 2016-08-10
TW202309014A (zh) 2023-03-01
KR102370067B1 (ko) 2022-03-04
JP2020019806A (ja) 2020-02-06
JP6883079B2 (ja) 2021-06-09
JP6461953B2 (ja) 2019-01-30
PH12016500818B1 (en) 2016-06-20
ME03792B (me) 2021-04-20
PH12016500818A1 (en) 2016-06-20
KR102617531B1 (ko) 2023-12-27
IL267773B (en) 2020-04-30
AU2019200404B2 (en) 2021-03-04
TWI775079B (zh) 2022-08-21
PE20160863A1 (es) 2016-09-03
CY1123164T1 (el) 2021-10-29
IL245314A0 (en) 2016-06-30
IL267773A (en) 2019-09-26
KR20210126157A (ko) 2021-10-19
EA201991770A1 (ru) 2019-12-30
CL2016001082A1 (es) 2016-12-09
PL3066085T3 (pl) 2020-11-02
WO2015070007A1 (en) 2015-05-14
MX366874B (es) 2019-07-29
US20150133674A1 (en) 2015-05-14
HRP20201089T1 (hr) 2020-10-30
TWI651311B (zh) 2019-02-21
US10280157B2 (en) 2019-05-07
CN105899498A (zh) 2016-08-24
JP6633163B2 (ja) 2020-01-22
EP3066085A1 (en) 2016-09-14
NZ719822A (en) 2021-11-26
AR098343A1 (es) 2016-05-26
HUE049337T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
CR20190351A (es) PROCESO PARA LA SINTESIS DE UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA (Divisional 2016-0252)
BR112019003914A2 (pt) inibidores de processos metabólicos celulares
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
GT201600123A (es) Inhibidores de syk
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
CR20160229A (es) Inhibidires de bromodominio
EA201490453A1 (ru) Замещенные аналоги (e)-n-(1-фенилэтилиден)бензогидразида в качестве ингибиторов деметилазы гистонов
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
PE20190181A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
NZ630196A (en) Cyclic amides as metap-2 inhibitors
CR20140553A (es) Compuestos de fenoxietil piperidina
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
DOP2016000120A (es) Nuevos inhibidores de dgat2
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
GT201400242A (es) "nuevos compuestos de pirazol"
EA201590700A1 (ru) Новый способ получения соединений для применения при лечении рака
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
CR20120653A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
EA201690936A1 (ru) Применение цистеамина и его производных для лечения митохондриальных заболеваний
BR112016016098A2 (pt) Compostos orgânicos
AR097890A1 (es) Compuestos de urea
EA201501177A1 (ru) Фармацевтические композиции
AR099931A1 (es) Combinaciones de agentes terapéuticos contra cáncer
TH166656A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง